PAX5 and chronic kidney disease: A CKD‐MBD biomarker panel, including BSAP and CTx, had good discrimination for low turnover (AUC 0.882; 95% CI, 0.731 to 1.000) that was superior to the individual miRNAs, but not to the miRNA panel.